{"entity":{"type":"insider","cik":"0001718557","url":"/insider/0001718557","json_url":"/insider/0001718557.json","name":"Cavazza Preta Martina","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":4,"first":"2017-12-01","last":"2020-05-04","span_basis":"filed_date"},"name_variants":[{"name":"Cavazza Preta Martina","source":"filing","n_filings":4,"first_seen":"2017-12-01","last_seen":"2020-05-04"}],"transactions":[{"id":2296431,"accession":"0001213900-20-010932","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-20-010932","line_url":"/filing/0001213900-20-010932#line-1","is_derivative":false,"issuer_cik":"0001092601","issuer_name":"FENNEC PHARMACEUTICALS INC.","issuer_ticker":"FENC","issuer_name_source":null,"issuer_url":"/issuer/0001092601","owner_cik":null,"owner_name":"Cavazza Enrico; CAVAZZA PAOLO; Cavazza Preta Martina; Cavazza Silvia; Essetifin SPA; Cavazza Francesca","owner_display_name":"Cavazza Enrico","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":768000.0,"shares_display":"768,000","price_per_share":6.25,"price_display":"6.25","price_state":"stated","total_value":4800000.0,"total_display":"4,800,000.00","total_whole":"4,800,000","shares_owned_after":3993694.0,"shares_owned_after_display":"3,993,694","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-04-30","filed_date":"2020-05-04","scope":"insider"},{"id":6427576,"accession":"0001213900-18-002972","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-18-002972","line_url":"/filing/0001213900-18-002972","is_derivative":false,"issuer_cik":"0000707511","issuer_name":"REGENERX BIOPHARMACEUTICALS INC","issuer_ticker":"RGRX","issuer_name_source":null,"issuer_url":"/issuer/0000707511","owner_cik":null,"owner_name":"Cavazza Preta Martina; Cavazza Francesca; Cavazza Silvia; Cavazza Enrico; Essetifin SPA; CAVAZZA PAOLO","owner_display_name":"Cavazza Preta Martina","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17933673.0,"shares_display":"17,933,673","price_per_share":0.23,"price_display":"0.23","price_state":"stated","total_value":4124744.79,"total_display":"4,124,744.79","total_whole":"4,124,745","shares_owned_after":25506521.0,"shares_owned_after_display":"25,506,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-13","filed_date":"2018-03-14","scope":"insider","n_lines":2},{"id":4667734,"accession":"0001213900-17-013250","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-17-013250","line_url":"/filing/0001213900-17-013250#line-1","is_derivative":false,"issuer_cik":"0001092601","issuer_name":"FENNEC PHARMACEUTICALS INC.","issuer_ticker":"FENC","issuer_name_source":null,"issuer_url":"/issuer/0001092601","owner_cik":null,"owner_name":"CAVAZZA PAOLO; Cavazza Francesca; Cavazza Enrico; Essetifin SPA; Cavazza Silvia; Cavazza Preta Martina","owner_display_name":"CAVAZZA PAOLO","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":294115.0,"shares_display":"294,115","price_per_share":8.5,"price_display":"8.50","price_state":"stated","total_value":2499977.5,"total_display":"2,499,977.50","total_whole":"2,499,978","shares_owned_after":3225694.0,"shares_owned_after_display":"3,225,694","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-12","filed_date":"2017-12-14","scope":"insider"},{"id":4232005,"accession":"0001213900-17-012851","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-17-012851","line_url":"/filing/0001213900-17-012851","is_derivative":false,"issuer_cik":"0000812796","issuer_name":"SOLIGENIX, INC.","issuer_ticker":"SNGX","issuer_name_source":null,"issuer_url":"/issuer/0000812796","owner_cik":null,"owner_name":"Cavazza Silvia; Cavazza Enrico; Cavazza Preta Martina; Cavazza Francesca; Essetifin SPA; Leadiant Biosciences, Inc.; CAVAZZA PAOLO","owner_display_name":"Cavazza Silvia","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":293510.0,"shares_display":"293,510","price_per_share":2.12,"price_display":"2.12","price_state":"stated","total_value":622241.2,"total_display":"622,241.20","total_whole":"622,241","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-29","filed_date":"2017-12-01","scope":"insider","n_lines":3},{"id":4231990,"accession":"0001213900-17-012851","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-17-012851","line_url":"/filing/0001213900-17-012851","is_derivative":false,"issuer_cik":"0000812796","issuer_name":"SOLIGENIX, INC.","issuer_ticker":"SNGX","issuer_name_source":null,"issuer_url":"/issuer/0000812796","owner_cik":null,"owner_name":"Cavazza Silvia; Cavazza Enrico; Cavazza Preta Martina; Cavazza Francesca; Essetifin SPA; Leadiant Biosciences, Inc.; CAVAZZA PAOLO","owner_display_name":"Cavazza Silvia","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":293510.0,"shares_display":"293,510","price_per_share":2.12,"price_display":"2.12","price_state":"stated","total_value":622241.2,"total_display":"622,241.20","total_whole":"622,241","shares_owned_after":271140.0,"shares_owned_after_display":"271,140","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-29","filed_date":"2017-12-01","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001211583","name":"FENNEC PHARMACEUTICALS INC.","url":"/issuer/0001211583","role":"Ten percent owner","n_filings":2,"first_seen":"2017-12-14","last_seen":"2020-05-04"},{"type":"issuer","type_label":"ISSUER","cik":"0000707511","name":"REGENERX BIOPHARMACEUTICALS INC","url":"/issuer/0000707511","role":"Ten percent owner","n_filings":1,"first_seen":"2018-03-14","last_seen":"2018-03-14"},{"type":"issuer","type_label":"ISSUER","cik":"0000812796","name":"SOLIGENIX, INC.","url":"/issuer/0000812796","role":"Other","n_filings":1,"first_seen":"2017-12-01","last_seen":"2017-12-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001718557","retrieved_at":"2026-08-24T11:10:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}